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“gold standard”, were set at 100%, while ranges for sensitivity
and speciﬁcity for MRA were drawn from literature and used
for sensitivity analysis. Analyses performed for a hypothetical
population of 91,665 (US diabetics with PAD who are eligible
for treatment in 2000) included: one-year total health care costs,
total Quality Adjusted Life Year Gained (QALYG; the increase
in quality of life after treatment), cost per QALYG, incremental
cost per QALY, and cost of accurate and inaccurate planning
with medical management, PTA, bypass, and amputation.
RESULTS: In the base-case scenario, with MRA sensitivity and
speciﬁcity at 98% and 83% respectively, the one-year per patient
total health care costs in the diabetic PAD population was
$20,176 for patients receiving an MRA versus $21,996 for those
receiving a DSA for treatment planning. The total QALYG were
higher in the MRA cohort than in the DSA cohort, 0.11 versus
0.07 respectively. Therefore, the total cost per QALYG was
$106,948 higher for patients who received a DSA ($190,697 vs.
$297,645). MRA dominates the DSA in incremental cost/QALY
with savings of $57,060, due to a lower risk of complication and
the resultant greater increase in QALYG and lower cost of treat-
ment. CONCLUSION: This model demonstrates that MRA as
a treatment-planning tool, with lower risk of complication, could
substantially reduce the cost and cost per quality-adjusted life
years for peripheral arterial disease in diabetic patients.
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OBJECTIVES: Nearly 600,000 patients are diagnosed with Deep
Vein Thrombosis (DVT) in US every year. One in every 100
patient dies due to pulmonary embolism developed as a later
complication. DVT during abdominal surgery is a frequent
problem & therefore prophylaxis is a compulsion. The objective
of this study was to identify the least costly prophylactic treat-
ment taking into account DVT complications from the health
care payer perspective. METHODS: Cost comparison was done
using a decision tree. The probabilities and costs for postopera-
tive DVT was obtained from clinical trial studies and other pub-
lished sources. Prophylaxis during surgery was considered to 
be for 9 days whereas treatment for postoperative DVT was
assumed to be for 5 days. Total cost included drug acquisition
cost, hospitalization costs for DVT. Expected value was com-
puted at each chance nodes. RESULTS: Fondaparinux sodium
has the least probability (0.042) for postoperative DVT compli-
cations whereas Enoxaparin sodium & unfractionated heparin
(UFH) have higher probabilities of 0.048 & 0.11 respectively.
The drug acquisition cost for prophylaxis was highest with fon-
daparinux sodium (2.5 mg) at $36.69, enoxaparin sodium (40
mg) at $24.74 & UFH (5000 IU) at $3.06 per single dose. Low
molecular weight heparins were given once daily while UFH was
given twice daily. Expected value was found to be $1129.720,
$1133.590 & $2256.730 for fondaparinux sodium, enoxaparin
sodium & UFH respectively. Sensitivity Analysis showed that the
model is somewhat inﬂuenced by adverse events & costs. CON-
CLUSION: Fondaparinux sodium has been found to have 
the least costly prophylactic treatment. Although the acquisition
cost is the highest, it is offset by the low probability of deve-
loping DVT complications and later hospitalization costs. UFH
even though having the lowest acquisition cost, has high rate 
of DVT complications & higher hospitalization cost due to 
frequent administration procedures & continuous monitoring
requirement.
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OBJECTIVES: To compare the costs resulting from a treatment
with ivabradine, a new medication for stable angina pectoris
patients, with standard care for those patients who cannot be
appropriately treated with standard medication in The Nether-
lands in 2006. METHODS: A decision analytic model was used
to estimate the cost-effectiveness of ivabradine in patients with
stable angina pectoris, who cannot be appropriately treated with
standard medication and are therefore currently candidates for
revacularisation (ESC guidelines 2006 on the management of
stable angina pectoris). Therefore ivabradine is compared with
standard care consisting of revascularization (CABG or PTCA).
The study was performed within the society perspective, which
included costs of medication and revascularisation procedures.
The data sources included published literature, the ivabradine
clinical trials, the Euro Heart Survey for stable angina, which
provided data from daily practice, and ofﬁcial price/tariff 
lists and national population statistics. RESULTS: Treatment
with ivabradine results in 77% reduction in revascularisation
and leads to a cost saving of €7028 per patient compared with
revacularisation during the ﬁrst year of treatment. Sensitivity
analyses showed that extrapolation beyond one year leads to
further cost savings. Another sensitivity analysis on the proba-
bility of revascularisation showed that cost savings vary from
€2882 to €9102. CONCLUSION: This model showed that the
use of ivabradine compares favourably with revascularisation in
treatment of stable angina pectoris in The Netherlands from a
budgetary and health economic perspective: the total costs are
substantially lower, whereas the effectiveness is at least similar.
Consequently ivabradine can be considered a cost-effective
treatment being dominant over standard care.
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OBJECTIVES: In Mexico in 2005, there are more than 250,000
patients in secondary prevention. One of the most serious and
frequent consequences of survivors of acute myocardial infarc-
tion (AMI) is heart failure, which is associated with a 55%
greater risk of dying and 2.15-times- greater risk of death or
recurrent AMI at 30 days. The purpose of this study was to 
evaluate the cost—effectiveness of eplerenone compared with
placebo from the Mexican health care payer’s perspective.
METHODS: We used a three-year analysis model to estimate
costs and effectiveness. Effectiveness measures were the num-
ber of life-year gained (LYG) and quality-adjusted life-years
(QALYs). Effectiveness data was obtained from the Eplerenone
Post-Acute Myocardial Infarction Heart Failure Efﬁcacy and
Survival Study (EPHESUS). Survival beyond the trial period (16
months) was estimated from data from the Framingham Heart
Study. The estimation of resource use was performed employing
local expert opinion surveys and they included hospitalization,
emergency room visits, outpatient services and medication. Costs
and life expectancy differences were discounted 5% annually.
Threshold sensitivity analysis was performed and acceptability
